ICON Public (NASDAQ:ICLR) Given New $262.00 Price Target at Truist Financial

ICON Public (NASDAQ:ICLR) had its target price decreased by stock analysts at Truist Financial from $284.00 to $262.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the medical research company’s stock. Truist Financial’s target price would indicate a potential upside of 40.70% from the stock’s previous close.

Several other research analysts also recently weighed in on ICLR. Royal Bank of Canada reissued an “outperform” rating and issued a $263.00 target price on shares of ICON Public in a research report on Wednesday, January 15th. JPMorgan Chase & Co. dropped their target price on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Robert W. Baird dropped their target price on shares of ICON Public from $249.00 to $225.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 20th. Finally, Leerink Partners reissued an “outperform” rating and issued a $255.00 target price (down from $270.00) on shares of ICON Public in a research report on Tuesday, November 19th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $283.92.

ICON Public Stock Performance

ICON Public stock opened at $186.21 on Thursday. The firm’s 50 day simple moving average is $204.84 and its 200-day simple moving average is $249.85. The company has a market cap of $15.36 billion, a P/E ratio of 20.76, a price-to-earnings-growth ratio of 1.78 and a beta of 1.19. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.34 and a quick ratio of 1.34. ICON Public has a fifty-two week low of $181.51 and a fifty-two week high of $347.72.

Institutional Trading of ICON Public

Institutional investors have recently added to or reduced their stakes in the business. Sierra Ocean LLC acquired a new stake in ICON Public in the fourth quarter valued at approximately $29,000. Park Place Capital Corp lifted its stake in ICON Public by 281.4% in the fourth quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 166 shares during the last quarter. Private Trust Co. NA lifted its stake in ICON Public by 48.8% in the fourth quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 82 shares during the last quarter. GAMMA Investing LLC lifted its stake in ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its stake in ICON Public by 23.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock valued at $147,000 after acquiring an additional 96 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.